Your browser doesn't support javascript.
loading
Which is the eligible patient to be treated with pioglitazone? The expert view.
Avogaro, A; Federici, M; Betteridge, J; Bonadonna, R; Campbell, I W; Schernthaner, G H; Staels, B; Farinaro, E; Crepaldi, G.
Afiliação
  • Avogaro A; Department of Clinical and Experimental Medicine, University of Padua, Via Giustiniani 2, 35128 Padua, Italy. angelo.avogaro@unipd.it
J Endocrinol Invest ; 34(10): 781-7, 2011 Nov.
Article em En | MEDLINE | ID: mdl-22234178
Pioglitazone has an important role in the treatment of patients with Type 2 diabetes. The drug can help patients to achieve sustained glycemic control and may delay the requirement for insulin. Pioglitazone may provide benefits beyond its effects on glycemia, with data suggesting it may confer anti-atherosclerotic and cardioprotective properties. Attention should be given to possible side effects relating to class effects of TZD, and selection of appropriate patients to be prescribed pioglitazone will enable optimum benefits to be derived from pioglitazone treatment.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tiazolidinedionas / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Limite: Animals / Humans Idioma: En Ano de publicação: 2011 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tiazolidinedionas / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Limite: Animals / Humans Idioma: En Ano de publicação: 2011 Tipo de documento: Article